Results 41 to 50 of about 101,750 (248)

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Frontiers in Immunology, 2023
The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, the number of mRNA vaccines in preclinical and clinical development increased exponentially since ...
Laura Matarazzo, Laura Matarazzo, Paulo J. G. Bettencourt, Paulo J. G. Bettencourt   +3 more
doaj   +1 more source

mRNA vaccine: a potential therapeutic strategy

Molecular Cancer, 2021
mRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production.
Yang Wang, Ziqi Zhang, Jingwen Luo, Xuejiao Han, Yuquan Wei, Xiawei Wei   +5 more
doaj   +1 more source

Excipients and mRNA vaccines

Journal of Excipients and Food Chemicals, 2020
None
Shireesh Apte
doaj  

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Vaccines, 2021
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease.
Maryam Bidram, Yue Zhao, Natalia G. Shebardina, Alexey V. Baldin, Alexandr V. Bazhin, Mohamad Reza Ganjalikhany, Andrey A. Zamyatnin, Mazdak Ganjalikhani-hakemi   +7 more
doaj   +1 more source

Development of mRNA rabies vaccines

Human Vaccines & Immunotherapeutics
Rabies, primarily transmitted to humans by dogs (accounting for 99% of cases). Once rabies occurs, its mortality rate is approximately 100%. Post-exposure prophylaxis (PEP) is critical for preventing the onset of rabies after exposure to rabid animals ...
Zixin Fang, Pengcheng Yu, Wuyang Zhu
doaj   +1 more source

A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA.

PLoS ONE, 2023
BackgroundCancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines ...
Andhika Rachman, Anggraini Iriani, Lugyanti Sukrisman, Wulyo Rajabto, Nadia Ayu Mulansari, Anna Mira Lubis, Rahmat Cahyanur, Findy Prasetyawati, Dimas Priantono, Bayu Bijaksana Rumondor, Rachelle Betsy, Samuel Juanputra   +11 more
doaj   +3 more sources

Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data

Frontiers in Public Health
mRNA vaccines, as a novel vaccine platform, have rapidly become a global research hotspot driven by the COVID-19 pandemic. This study employs a systematic analysis method based on clinical trial registries to conduct a descriptive statistical analysis of
Sijia Liu, Tiange Zhou, Mengmeng Wang, Wanwan Xiang, Jiancai Wu   +4 more
doaj   +1 more source

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic

Frontiers in Immunology, 2023
The advent of mRNA vaccines represents a significant advance in the field of vaccinology. While several vaccine approaches (mRNA, DNA, recombinant protein, and viral-vectored vaccines) had been investigated at the start of the COVID-19 pandemic, mRNA ...
Ziyang Xu, David E. Fisher
doaj   +1 more source

mRNA Innovates the Vaccine Field [PDF]

Vaccines, 2021
Development of new vaccine modalities is a critical need to address many of the shortcomings of traditional platforms such as the lack of sufficient efficacy against certain pathogens or cancer; difficulties with production; or, in some cases, safety issues [...]
openaire   +3 more sources

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source